Background: Most long-term heavy drinkers do not have clinically evident chronic liver disease (CLD). However, at any time-point, their risk of developing CLD remains unknown. We aimed to evaluate the long-term outcomes of a group of heavy drinkers, without evidence of CLD at baseline.

Methods: A cohort of 123 long-term heavy drinkers without CLD were prospectively recruited in 2002 and retrospectively followed until 2018.

Results: At baseline (2002), median alcohol consumption was 271±203g/day during 21.5±20 years, 65% being abstinent during the previous 1.75±5 months. Patients were followed for 14±3 years. During follow-up, 53% reported any alcohol intake. Alcohol consumption during follow-up associated weakly with either 1- or 6-months previous abstinence at baseline. Until 2018, progression to CLD occurred in 6%, associating with years of alcohol intake during follow-up (OR 1.15 [1.01-1.31]) and baseline alkaline-phosphatase (OR 1.05 [1.01-1.10]). During follow-up, being abstinent for at least 1 year positively associated with CLD-free survival. 27% died (55% of cancer-mostly oropharyngeal cancer, 27% of cardiovascular disease, and 9% of liver disease), with a mean age of 71 years [69-74] (10 years less than the expected in the Portuguese population). Achieving abstinence for at least 1 year positively associated with overall survival, while smoking, and hepatic steatosis at baseline associated negatively.

Conclusion: Long-term heavy drinkers seemed to have a decreased life expectancy compared with the overall Portuguese population. Cancer was the main cause of death. Our results suggest that progression to CLD depends mostly on continued alcohol intake. Alcohol abstinence, even if temporary, seems to decrease the risks of CLD and mortality.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148371PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0252218PLOS

Publication Analysis

Top Keywords

liver disease
16
heavy drinkers
16
long-term heavy
12
alcohol intake
12
chronic liver
8
years follow-up
8
alcohol consumption
8
intake alcohol
8
progression cld
8
year positively
8

Similar Publications

Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.

J Gastroenterol

January 2025

Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.

Background: Advanced liver fibrosis in cases of metabolic dysfunction-associated steatotic liver disease (MASLD) leads to cirrhosis and hepatocellular carcinoma. The current gold standard for liver fibrosis is invasive liver biopsy. Therefore, a less invasive biomarker that accurately reflects the stage of liver fibrosis is highly desirable.

View Article and Find Full Text PDF

Background: Both laparoscopic hepatectomy (LH) and robotic hepatectomy (RH) have been performed for tumors in nearly all liver segments. However, few studies have compared the outcomes of patients who underwent open hepatectomy (OH), LH and RH for the treatment of Barcelona Clinic Liver Cancer (BCLC) stage 0-A HCC in S7/8.

Methods: The clinical data of patients who underwent S7/8 resection for the treatment of BCLC stage 0-A HCC in the First Affiliated Hospital of Guangxi Medical University from July 2017 to July 2023 were retrospectively collected.

View Article and Find Full Text PDF

VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8T cells function in the HCC microenvironment.

Signal Transduct Target Ther

January 2025

Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

CD8T cells within the tumor microenvironment (TME) are often functionally impaired, which limits their ability to mount effective anti-tumor responses. However, the molecular mechanisms behind this dysfunction remain incompletely understood. Here, we identified valosin-containing protein (VCP) as a key regulator of CD8T cells suppression in hepatocellular carcinoma (HCC).

View Article and Find Full Text PDF

Rationale And Objectives: The purpose of this study was to demonstrate the impact of postoperative adjuvant transarterial chemoembolization (TACE) on the prognosis of patients with macrotrabecular-massive hepatocellular carcinoma (MTM-HCC).

Materials And Methods: This retrospective study used the clinical records of patients with resected MTM-HCC with/without adjuvant TACE at three centers between January 2015 and December 2022. The primary end point was recurrence free survival (RFS).

View Article and Find Full Text PDF

Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection.

J Formos Med Assoc

January 2025

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan. Electronic address:

Background: Limited data exists regarding the long-term serum ferritin dynamics following sustained virologic response (SVR) and factors associated with trends in changes among patients undergoing treatment for hepatitis C virus (HCV).

Methods: Serum ferritin levels were assessed biannually in 1538 participants undergoing direct-acting antivirals (DAAs) or peginterferon plus ribavirin (PR) with a median of follow-up of 5.0 years after off-treatment week 12.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!